Kornitzer Capital Management Inc. KS Sells 20,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Kornitzer Capital Management Inc. KS decreased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,291 shares of the company's stock after selling 20,000 shares during the period. Kornitzer Capital Management Inc. KS owned 0.28% of TransMedics Group worth $7,206,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ancora Advisors LLC bought a new stake in TransMedics Group in the 1st quarter valued at about $38,000. First Horizon Advisors Inc. grew its position in TransMedics Group by 45.1% in the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock valued at $41,000 after purchasing an additional 169 shares during the period. Belpointe Asset Management LLC grew its position in TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company's stock valued at $42,000 after purchasing an additional 190 shares during the period. PNC Financial Services Group Inc. grew its position in TransMedics Group by 595.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company's stock valued at $50,000 after purchasing an additional 512 shares during the period. Finally, Comerica Bank acquired a new stake in TransMedics Group in the 3rd quarter valued at $34,000. Institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 3.5 %

TMDX stock traded down $3.08 during trading on Friday, reaching $84.16. The stock had a trading volume of 961,315 shares, compared to its average volume of 844,745. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $99.63. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69. The company's 50 day moving average is $82.88 and its two-hundred day moving average is $73.49. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -109.30 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. The business's revenue was up 158.6% on a year-over-year basis. Equities research analysts forecast that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TMDX shares. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Oppenheimer raised their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a research report on Tuesday, February 27th. Finally, Piper Sandler assumed coverage on TransMedics Group in a research report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus target price of $102.00.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 2,330 shares of TransMedics Group stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the sale, the insider now owns 14,375 shares of the company's stock, valued at $1,295,043.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the firm's stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company's stock, valued at $7,044,932.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 2,330 shares of the firm's stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $90.09, for a total value of $209,909.70. Following the completion of the sale, the insider now directly owns 14,375 shares of the company's stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 119,408 shares of company stock valued at $10,182,881. Insiders own 6.70% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.